Magierski_2015_Neurodegener.Dis.Manag_5_445

Reference

Title : Benefits and risks of add-on therapies for Alzheimer's disease - Magierski_2015_Neurodegener.Dis.Manag_5_445
Author(s) : Magierski R , Sobow T
Ref : Neurodegener Dis Manag , 5 :445 , 2015
Abstract :

Despite three decades of intensive research, the efforts of scientific society and industry and the expenditures, numerous attempts to develop effective treatments for Alzheimer's disease have failed. Currently, approved and widely used medications to treat cognitive deficits in Alzheimer's disease are symptomatic only and show at best modest efficacy. In this context, the need to develop a successful, disease-modifying treatment is loudly expressed. One way to achieve this goal is the use of add-on therapies or various combinations of existing 'conventional' drugs. Results of several clinical studies and post hoc analyses of combination therapy with all cholinesterase inhibitors and memantine are published. Moreover, there is a need for studies on long-term efficacy of combination therapy in Alzheimer's.

PubMedSearch : Magierski_2015_Neurodegener.Dis.Manag_5_445
PubMedID: 26517312

Related information

Citations formats

Magierski R, Sobow T (2015)
Benefits and risks of add-on therapies for Alzheimer's disease
Neurodegener Dis Manag 5 :445

Magierski R, Sobow T (2015)
Neurodegener Dis Manag 5 :445